➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Last Updated: July 6, 2020

DrugPatentWatch Database Preview


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Triamcinolone Acetonide, and what generic alternatives are available?

Triamcinolone Acetonide is a drug marketed by Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Cosette, Fougera Pharms, Glenmark Pharms Ltd, Lupin Atlantis, Macleods Pharms Ltd, MLV, Morton Grove, Mylan, Perrigo New York, Pharmaderm, Pharmafair, Strides Pharma, Taro, Taro Pharm Inds Ltd, Teligent Pharma Inc, Topiderm, Amneal, Parnell, Sandoz Inc, Teva Pharms Usa, Watson Labs, Akorn, Saptalis Pharms, Wockhardt Bio Ag, Encube, Glenmark Pharms, Novel Labs Inc, Lyne, Perrigo Israel, Perrigo Uk Finco, Rising, and Cmp Pharma Inc. and is included in eighty-four NDAs.

The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

US ANDA Litigation and Generic Entry Outlook for Triamcinolone Acetonide

A generic version of TRIAMCINOLONE ACETONIDE was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Start Trial

Drug patent expirations by year for TRIAMCINOLONE ACETONIDE


Drug Sales Revenue Trends for TRIAMCINOLONE ACETONIDE

See drug sales revenues for TRIAMCINOLONE ACETONIDE

Recent Clinical Trials for TRIAMCINOLONE ACETONIDE

Identify potential brand extensions & 505(b)(2) entrants

Austin V StonePhase 2
Tanta UniversityPhase 2/Phase 3
Kasr El Aini HospitalPhase 4

See all TRIAMCINOLONE ACETONIDE clinical trials

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE ACETONIDE

US Patents and Regulatory Information for TRIAMCINOLONE ACETONIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 085691-003 Approved Prior to Jan 1, 1982 AT RX No No   Start Trial   Start Trial   Start Trial
Cosette TRIAMCINOLONE ACETONIDE triamcinolone acetonide PASTE;DENTAL 205592-001 Jan 12, 2017 AT RX No No   Start Trial   Start Trial   Start Trial
Taro TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 086275-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.